Sofosbuvir/RBV-based therapy yielded marked clinical improvement and/or disease stabilization in 75% of patients and was well tolerated; however, serious adverse events were common in this very sick patient population.
Meta-analysis of data from 10 patient cohort studies found that the ongoing risk of developing HCC for patients with HCV-induced cirrhosis and who achieve SVR is approximately 1% with the risk increasing with advanced age, more severe liver disease, or diabetes.
In a phase III trial, 76% of patients with genotype 1 HCV achieved SVR12 with 24 weeks of therapy; 88% of patients with genotype 2 HCV and 67% with genotype 3 HCV achieved SVR12 with 12 weeks of therapy.
Patients who achieved > 30 consecutive days with HCV RNA target not detected before transplantation were highly likely to remain free of HCV recurrence 12 weeks after transplantation.
Patients experiencing recurrence of genotype 1 HCV infections following liver transplantation achieved SVR12 with boceprevir plus pegIFN/RBV of 51% and 41% achieved SVR12 with telaprevir plus pegIFN/RBV, but ≥ 50% discontinued therapy due to adverse events or virologic failure.
The HBV reactivation rate for patients anti-HBsAg negative, anti-HBcAg positive is 24.2% when they are treated with rituximab-based chemotherapy for hematologic malignancies.
A total of 72% of HCV/HIV-coinfected patients achieved undetectable HCV RNA after 12 weeks of treatment with telaprevir plus pegIFN/RBV and 99% maintained HIV-1 RNA < 50 copies/mL while on therapy.
The majority of patients in the registry who received telaprevir- or boceprevir-based triple therapy had a previous nonresponse to treatment (62%), and most received telaprevir vs boceprevir (76% vs 24%).
Pilot study finds 24-week treatment leads to HCV RNA negativity in all patients by Week 4, which is sustained throughout therapy; SVR4 rate of 77% at interim analysis.
In this large cohort of patients from 2 earlier studies with long-term follow-up, fibrosis stage was found to be more accurate than NAS for predicting overall and disease-specific mortality.
In this pilot study, preliminary data reveal disproportionately high HCV prevalence rates among males and the uninsured/underinsured.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.